☆ 4.7 Meeting Abstract

A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC)

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 38, Issue 6, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

Keywords

-

Categories

Oncology

Funding

  1. Eisai Inc., Woodcliff Lake, NJ, USA
  2. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.